EyePoint, Inc. (NASDAQ: EYPT) Securities Class Action USDC – Eastern District of New York november 18, 2026 CLASS PERIOD: may 27, 2025 – august 14, 2026LEAD PLAINTIFF DEADLINE: january 19, 2027 Please complete the form below to contact Kaplan Fox regarding the EyePoint class action: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol * Please Insert Your Estimation Of Losses In USD * Are you a current employee of the company mentioned having traded above? * Yes No Are you a former employee of the company mentioned having traded above? * Yes No Would you like to receive Kaplan Fox Investor Alerts? * Yes No How would you like to send your transactions? Copy & Paste Upload Statements or Excel Workbook Type Transaction In Submit Transactions Here or Type Below: Drop a file here or click to upload Choose File Maximum file size: 52.43MB Typed Transactions Security Transaction BuySell Trade Date Quantity Price Add Another Transaction Remove Copy Transactions into the field below Submit If you are human, leave this field blank. Principal Contacts Pamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com About the EyePoint class action lawsuit A securities class action has been filed against EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or otherwise acquired EyePoint securities between May 27, 2025 and August 14, 2026 (the “Class Period”). The case was filed in the U.S. District Court for the Eastern District of New York. Investors who want to ask the court to appoint them lead plaintiff must do so by January 19, 2027. If you invested in EyePoint during the Class Period and suffered losses, contact Kaplan Fox using the form on this page, by emailing pmayer@kaplanfox.com, or by calling (646) 315-9003. What the lawsuit alleges According to the complaint, EyePoint’s lead product candidate is DURAVYU and during the Class Period Eyepoint was evaluating DURAVYU for the treatment of wet age-related macular degeneration in the Company’s Phase 3 LUGANO and LUCIA trials. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) DURAVYU was less effective than Defendants had led investors to believe; (ii) accordingly, DURAVYU’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times. What happened to EyePoint stock According to the complaint, the truth began to emerge on August 17, 2026, when EyePoint issued a press release announcing topline results from the LUGANO trial. The complaint alleges that the press release disclosed, in relevant part, that “the primary endpoint of change from baseline in best corrected visual acuity (BCVA) versus 2 mg aflibercept on-label control was not achieved in the full dataset, confounded by [an] asymmetric cohort.” On this news, EyePoint’s stock price fell $9.88 per share, or 66.98%, to close at $4.87 per share on August 17, 2026. Who may be eligible The proposed class includes investors who purchased or otherwise acquired EyePoint securities between May 27, 2025 and August 14, 2026. If you bought during that period and suffered losses, you may be a member of the class. Lead plaintiff deadline: January 19, 2027 A lead plaintiff is an investor the court appoints to represent the class and oversee the case on its behalf. Class members who want to serve in that role must move the court no later than January 19, 2027. You need not seek to become a lead plaintiff in order to share in any possible recovery. If you have losses, contact us to learn more about the lead plaintiff process. Case updates January 19, 2027: Deadline to ask the court to be appointed lead plaintiff. Frequently asked questions Do I have to become lead plaintiff to recover? No. You need not seek to become a lead plaintiff in order to share in any possible recovery. What if I bought EyePoint outside the Class Period? The complaint as filed covers purchases between May 27, 2025 and August 14, 2026. Contact us if you are not sure whether your purchases qualify. WHY CONTACT KAPLAN FOX? Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented. Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch. For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT: Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003pmayer@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1501Oakland, California 94612(415) 772-4704lking@kaplanfox.com Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Kaplan Fox Files GoDaddy, Inc. Class Action: Learn More Now See the Case Build-A-Bear Workshop, Inc. (NYSE: BBW) Securities Class Action See the Case Alibaba Group Holding Limited (NYSE: BABA) Securities Class Action See the Case Advanced Micro Devices (AMD) Investigation | Kaplan Fox See the Case Lennar (LEN) Class Action Lawsuit | Kaplan Fox See the Case NuScale Power (SMR) Class Action Lawsuit | Kaplan Fox See the Case Portillo’s Inc. (NASDAQ: PTLO) Securities Class Action See the Case Intel Corporation (NASDAQ: INTC) Securities Class Action See the Case Once Upon a Farm, PBC (OFRM) Investigation | Kaplan Fox See the Case Arbor Realty Trust, Inc. (NYSE: ABR) Securities Class Action See the Case NVIDIA Corporation (NASDAQ: NVDA) Securities Class Action See the Case CVRx (CVRX) Class Action Lawsuit | Kaplan Fox See the Case